Clinical Trial: A single-arm, multicenter, prospective clinical study of Trastuzumab rezetecan combined with Adebrelimab and gemcitabine for the conversion treatment of biliary malignancies with HER2 mutations or overexpression (China)

China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-arm, multicenter, prospective clinical study of Trastuzumab rezetecan combined with Adebrelimab and gemcitabine for the conversion treatment of biliary malignancies with HER2 mutations or overexpression'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132885

Registration Time: 2026/09/20

Type: Interventional study

Primary Sponsor: Zhongshan Hospital Affiliated to Xiamen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343623

Published by HT Digital Content Services with permission from Health Daily Digest....